Cytokinetics analyst coverage

Web1 day ago · Similarly, MAC has 32.06% upside from the recent share price of $9.92 if the average analyst target price of $13.10/share is reached, and analysts on average are expecting HR to reach a target ... WebCYTK Stock 12 Months Forecast. $58.50. (66.24% Upside) Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19.

CYTK - Cytokinetics Inc Stock Price Quote - NASDAQ Morningstar

WebFeb 27, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK - Get Rating) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports.One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy … Web17 rows · ANALYST COVERAGE. Cytokinetics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Cytokinetics, Inc. 's performance made by these analysts are theirs alone and do not represent opinions, … orc 2925.11 5 https://mjcarr.net

SEC FILINGS Cytokinetics, Inc.

WebMay 24, 2024 · Below is a summary of how these 4 analysts rated Cytokinetics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … WebAnalyst Estimates Options Snapshot Stock Price Targets Yearly Numbers Estimates CYTK will report 2024 earnings on 02/23/2024 EPS Estimate 2024 2024 2024 2024 -10 -5 0 … Web17 rows · Mar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference … ipr by declaration

Cytokinetics Reports Fourth Quarter 2024 Financial Results

Category:Analysts Have Conflicting Sentiments on These …

Tags:Cytokinetics analyst coverage

Cytokinetics analyst coverage

Inspire Investing LLC Buys 828 Shares of Cytokinetics, …

WebApr 12, 2024 · Wall Street Analyst Weigh In. Several brokerages recently weighed in on CYTK. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a ... WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class …

Cytokinetics analyst coverage

Did you know?

WebMar 31, 2024 · March 31, 2024 Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. March 27, 2024 Cytokinetics Releases Inaugural Corporate Responsibility Report. March … WebOct 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential...

WebApr 2, 2024 · Financials. In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods of 2024. This ... WebMay 10, 2024 · Following the latest downgrade, the ten analysts covering Cytokinetics provided consensus estimates of US$17m revenue in 2024, which would reflect a painful …

WebJan 9, 2024 · By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 14% per year. ... We have analyst estimates for Cytokinetics ... WebJan 7, 2024 · Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten; Royalty Pharma Purchases Royalties on Future Sales of Aficamten; Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET; NEW YORK, NY and SOUTH SAN FRANCISCO, …

WebJul 19, 2024 · The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) ( United States and Canada ) or (706) 679-3078 (international) and typing in the passcode 2984784.

WebMar 7, 2024 · Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Mizuho Posted by Defense World Staff on Mar 7th, 2024 Mizuho assumed coverage on shares of Cytokinetics ( NASDAQ:CYTK – Get... orc 2930.01WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth … orc 2925.11 a c 1 bWebApr 6, 2024 · Analyst Price Forecast Suggests 12.99% Upside As of April 6, 2024, the average one-year price target for Broadcom is $696.81. The forecasts range from a low of $589.84 to a high of $787.50. orc 2935WebApr 5, 2024 · According to analysts' consensus price target of $56.21, Cytokinetics has a forecasted upside of 60.7% from its current price of $34.99. Amount of Analyst … orc 2950.01WebAnalyst Coverage; Investor FAQ; IR/Media Contacts; Corporate Governance; Information Request; Email Alerts ipr check testerWebFor more in-depth coverage of Tesla Motors, ... Analyst Price Forecast Suggests 12.52% Upside. As of April 6, 2024, the average one-year price target for Tesla Motors is $203.14. The forecasts ... orc 2951WebMar 31, 2024 · Mar. 31, 2024, 04:01 PM Over the past 3 months, 13 analysts have published their opinion on Cytokinetics (NASDAQ:CYTK) stock. These analysts are typically employed by large Wall Street banks and... orc 2950